SIGLECL1 Inhibitors
Chemical inhibitors of SIGLECL1 act through a variety of mechanisms to inhibit the protein's function by targeting signaling pathways involved in its regulation and activity. Erlotinib, a known EGFR inhibitor, downregulates EGFR-mediated signaling pathways, which are crucial for SIGLECL1 function. Similarly, Dasatinib, by inhibiting Src-family tyrosine kinases, disrupts multiple signaling pathways, including those where SIGLECL1 plays a role. CI-1033 targets the ErbB family of tyrosine kinases, which are important for the cellular processes that involve SIGLECL1, thereby inhibiting its function. Another molecule, GW2580, by inhibiting the CSF-1 receptor, affects downstream signaling that may involve SIGLECL1. PP2, being a selective Src-family kinase inhibitor, prevents the activation of pathways that are essential for SIGLECL1's activity.
Further inhibitory effects on SIGLECL1 come from small molecules targeting various other kinases and signaling molecules. LY294002, a PI3K inhibitor, likely affects SIGLECL1 function by altering the PI3K signaling pathway. U0126 and PD98059, both MEK inhibitors, suppress the MAPK/ERK pathway, which is important for the regulation of SIGLECL1. SP600125, a JNK inhibitor, and SB203580, a p38 MAP kinase inhibitor, each target specific MAP kinases that are potentially involved in the pathways regulating SIGLECL1. Wortmannin, another PI3K inhibitor, leads to the functional inhibition of SIGLECL1 by interfering with PI3K-dependent processes. Lastly, Lapatinib, which targets both EGFR and HER2 receptors, disrupts signaling pathways that may be necessary for SIGLECL1's function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that could inhibit SIGLECL1 by downregulating EGFR-mediated signaling pathways involved in cellular processes where SIGLECL1 is implicated. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src-family tyrosine kinase inhibitor, is known to inhibit multiple tyrosine kinases. This inhibition could disrupt signaling pathways that are crucial for functions where SIGLECL1 is involved, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective Src-family kinase inhibitor. By inhibiting Src kinases, PP2 could prevent downstream signaling that is essential for SIGLECL1's activity, thereby inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. PI3K signaling is crucial for various cellular functions, and its inhibition by LY294002 could lead to the functional inhibition of SIGLECL1 through the downregulation of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase (MEK), which is part of the MAPK/ERK pathway. Inhibiting MEK could lead to the suppression of cellular processes in which SIGLECL1 is active, resulting in its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor, which could disrupt the MAPK/ERK signaling pathway. This disruption could inhibit the functional role of SIGLECL1 in cells. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 could impair signaling pathways that are required for SIGLECL1-mediated functions, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. The inhibition of p38 MAPK could lead to the attenuation of cellular responses in which SIGLECL1 is implicated, thus functionally inhibiting SIGLECL1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. The inhibition of PI3K signaling by Wortmannin could lead to the functional inhibition of SIGLECL1 by affecting the cellular processes it is involved in. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2. By inhibiting these receptors, Lapatinib could disrupt signaling pathways that SIGLECL1 may rely on for its function, thus leading to its inhibition. | ||||||